Amid a spurt in COVID-19 cases, apex health research body ICMR has decided to conduct a study in 75 affected districts across the country to identify people who were exposed to the novel coronavirus infection and yet showed mild or no symptoms.
The study can help ascertain whether there has been community transmission of the respiratory disease in those areas or not, official sources said.
The death toll due to COVID-19 rose to 1,886 and the number of cases climbed to 56,342 on Friday registering an increase of 103 deaths and 3,390 cases in the last 24 hours since Thursday morning, according to Union health ministry data.
"As a part of the study, people from red, orange and green zones in a district will be tested for COVID-19 at random to check whether they have developed antibodies against the infection even though they remained asymptomatic or showed mild symptoms.
"The presence of antibody in them will establish that they were infected by the virus and were able to fight it off. They did not know they had contracted the disease as they had no symptoms," an official explained.
The exercise will also help ascertain if there has been community spread of the disease, the official said. Community spread is a stage where the source of the infection cannot be traced.
Scientists at the Indian Council of Medical Research (ICMR) aim to begin the study at the earliest.
Districts with high population and heavy inter-state movement of people will be selected for the study to represent the respective state, the sources said.
According to a study, around 80 per cent of coronavirus infected people show mild or no symptoms of the illness.
Officials said the study would have started earlier as it was planned to be conducted with the rapid antibody test kits brought from China. But after those test kits showed inaccurate results in some places, the study had to be postponed.
"The quantum of sampling for the study is yet to be decided. The study will only make sense if it has a decent sample size," another official said.
The modality of testing is yet to be decided, but according to sources, either an ELISA antibody test which is a kind of blood test or pool sampling with RT-PCR test could be used for the study, the official sources said.
The ELISA (enzyme-linked immunosorbent assay) test kits are awaiting ICMR's validation, which is expected soon, they said.
The ELISA test is similar to rapid antibody tests as it looks for antibodies in the blood to ascertain if one has been infected with the coronavirus infection or not.
A pooled testing algorithm involves the PCR screening of a specimen pool comprising multiple individual patient specimens, followed by individual testing only if a pool screens positive.
At present, efforts are being made by the government to identify asymptomatic people through contact tracing and community surveillance.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
